BPC-157 Capsules: What the Oral-Route Evidence Shows

The clearest oral-route evidence for BPC-157 is a series of rat studies from the peptide's discovery group, in which BPC-157 was dissolved and given continuously in the animals' drinking water rather than injected. In a rat model of prolonged esophagitis with sphincter failure, BPC-157 given in drinking water alongside a separate intraperitoneal-injection arm recovered esophagitis lesions and normalised pressure in both the lower esophageal and pyloric sphincters, assessed macroscopically, microscopically and by manometry.^[2]

In a rat colocutaneous-fistula model, BPC-157 given in drinking water until the animals were euthanised at set points from day 1 to day 28 after surgery accelerated the healing of both the colonic and skin defects, closing the fistula tract on the same macroscopic, microscopic and functional (leak-pressure) measures used for the injected arm of the same experiment.^[3]

A 2021 rat study of surgically detached quadriceps myotendinous junctions used six rats per group at each of four post-operative intervals (7, 14, 28 and 42 days), comparing intraperitoneal BPC-157 against BPC-157 given perorally in drinking water. Both routes produced comparable recovery — counteracted muscle atrophy and visibly repaired defects by day 28–42 — on macroscopic, microscopic, biomechanical and functional testing.^[4]

PubMed and ClinicalTrials.gov do not list a completed, published clinical trial that gave BPC-157 to people by the oral route. The published human pilot work on BPC-157 is small and is covered in full elsewhere on this site — see BPC-157 side effects and BPC-157: the complete guide rather than repeating it here — and none of it used an oral formulation. The one BPC-157 study currently registered on ClinicalTrials.gov, a Phase 2 trial in acute hamstring strain, also uses an injectable (subcutaneous) route and had not reported results as of September 2026.^[7]

That gap between animal-model testing and human testing on the same route is what a capsule buyer cannot see from a product listing.

A capsule bought online is a finished consumer product, not a research reference standard. Its label can claim a peptide name and a milligram amount; neither claim is self-verifying. Confirming that the intended peptide is actually present, at the stated purity, and free of degradation products or synthesis byproducts requires the same identity and purity testing used for any other peptide format — mass-spectrometry identity confirmation and HPLC purity analysis, read alongside the method and batch details.

Encapsulation also adds a manufacturing step that a lyophilised vial does not have: a filler or excipient blend, a fill-weight process, and often a coating, each of which can affect how much intact peptide is actually in a given capsule versus what the label states. None of that is visible from a product photo or a marketing claim about gastric stability; it is only checkable from a batch-matched certificate of analysis, read the way the linked guides describe.

In the United States, FDA evaluates bulk substances nominated for use in compounded medicines and places those that may present significant safety risks in "category 2" of its interim compounding policies. BPC-157 was previously in category 2, with FDA citing a possible risk of immunogenicity for certain routes of administration, complexities with peptide-related impurities and characterisation of the active ingredient, and no or only limited safety-related information. On FDA's page, current as of 22 April 2026, BPC-157 appears among the substances "nominated but withdrawn": its nominators withdrew the nomination, and it is not on the active category 2 list.^[5]

In sport, the World Anti-Doping Agency's Prohibited List names BPC-157 directly. The 2026 List, effective 1 January 2026, places it under section S0, Non-Approved Substances — pharmacological substances with no current approval by any governmental regulatory health authority for human therapeutic use — and names BPC-157 by name as one of the substances that class covers. S0 substances are prohibited at all times, in and out of competition, and the List does not carve out an exception for a particular route or formulation such as a capsule.^[6]

The research literature and the human regulatory record point in different directions on route. In the published rat studies above, the oral (drinking-water) route and the injected (intraperitoneal) route were often tested side by side in the same experiment, and the papers report comparable outcomes between the two routes for the specific models tested — esophagitis healing, fistula closure, myotendinous-junction repair.^[2][3][4]

At the human level, the comparison cannot be made the same way. Every published human pilot data point and the one currently registered human trial use an injected route; no published human study has tested oral BPC-157 against an injected comparator, or against placebo, in the same trial. That means the "oral vs injectable" question has an answer in specific rodent models and no answer yet in people — a research-evidence gap, not a reason to prefer one route over the other for any purpose this site describes.^[7]

Peptyds supplies BPC-157 as a single lyophilised research vial — BPC-157 Complex — intended for laboratory research use. Peptyds does not sell an oral capsule, tablet, or any other oral-route BPC-157 product, and nothing in this article describes a Peptyds product being taken by mouth, or by any other route, by a person.